EU regulator starts real-time review of Merck's COVID-19 pill

Norge Nyheter Nyheter

EU regulator starts real-time review of Merck's COVID-19 pill
Norge Siste Nytt,Norge Overskrifter
  • 📰 Reuters
  • ⏱ Reading Time:
  • 14 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 9%
  • Publisher: 97%

U.S. drugmaker Merck & Co Inc said on Monday the European Union's drug regulator has initiated a real-time review of its experimental COVID-19 antiviral drug for adults.

The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermidsaid on Monday the European Union's drug regulator has initiated a real-time review of its experimental COVID-19 antiviral drug for adults.

While vaccines are the main weapons against COVID-19, Merck's experimental pill molnupiravir could be a game-changer after studies showed it could halve the chances of dying or being hospitalised for those most at risk of contracting severe illness.

Vi har oppsummert denne nyheten slik at du kan lese den raskt. Er du interessert i nyhetene kan du lese hele teksten her. Les mer:

Reuters /  🏆 2. in US

Norge Siste Nytt, Norge Overskrifter

Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.

Moderna says its COVID-19 vaccine is protective, safe in kids 6 to 11Moderna says its COVID-19 vaccine is protective, safe in kids 6 to 11Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults.
Les mer »

Moderna Says Its Low-Dose COVID-19 Vaccine Works For Kids 6 To 11Moderna Says Its Low-Dose COVID-19 Vaccine Works For Kids 6 To 11Children who received the vaccine developed virus-fighting antibodies similar to levels that young adults produce after full-strength shots, Moderna said.
Les mer »

Moderna says its COVID-19 vaccine protective, safe in young childrenModerna says its COVID-19 vaccine protective, safe in young childrenModerna Inc said on Monday its COVID-19 vaccine generated a strong immune response and was generally well-tolerated in children aged six to 11 years, and the company plans to submit the data to regulators soon.
Les mer »

Moderna Data Shows Covid-19 Vaccine Produced Strong Immune Response in 6- to 11-Year-OldsModerna Data Shows Covid-19 Vaccine Produced Strong Immune Response in 6- to 11-Year-OldsModerna said it would submit the results from an interim study to health regulators in the U.S., Europe and elsewhere in seeking authorization for 6- to 11-year-olds.
Les mer »

How to talk to your younger kids about the Covid-19 vaccineHow to talk to your younger kids about the Covid-19 vaccineCNN News, delivered. Select from our newsletters below and enter your email to subscribe.
Les mer »

New York City Inches Toward Covid-19 Becoming EndemicNew York City Inches Toward Covid-19 Becoming EndemicNew York City’s high rates of vaccination, some prior infection and precautions are keeping the worst outcomes of Covid-19 in check, epidemiologists say. “We’re on our way to an endemic phase.”
Les mer »



Render Time: 2025-03-09 19:36:21